RE: Under the Radar19 Feb 2026 08:19
Dr Alastair Smith, Chair Commented:
"TheraCryf presents one of the most compelling investment opportunities that I have recently been introduced to. The primary near-term value driver is a potential treatment for addiction; a market that already exceeds $40bn and is expected to grow substantially in the coming years to address the human and economic costs of a broad range of addictions from opioids, to alcohol, to food and binge eating.